Leaflet PEMETREXED SANDOZ 25mg / ml concentrate for solution for infusion


Indicated for: non-small cell lung cancer

Substance: pemetrexeda (antimetabolite antineoplastic)

ATC: L01BA04 (Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues)

Pemetrexed is a chemotherapy agent used in the treatment of lung cancer and malignant pleural mesothelioma. It works by inhibiting enzymes involved in DNA and RNA synthesis, thereby preventing tumor cell growth.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.

Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.

General data about PEMETREXED SANDOZ 25mg / ml

  • Substance: pemetrexeda
  • Date of last drug list: 01-05-2026
  • Commercial code: W67349002
  • Concentration: 25mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 783.72 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: EBEWE PHARMA GES.M.B.H NFG. KG - AUSTRIA
  • Holder: SANDOZ S.R.L. - ROMANIA
  • Number: 13452/2020/02
  • Shelf life: 2 years

Concentrations available for pemetrexeda

  • 1000mg
  • 100mg
  • 10mg/ml
  • 25mg/ml
  • 500mg

Compensation lists for PEMETREXED SANDOZ 25mg / ml Sandoz

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

783.72 RON

783.72 RON

0.00 RON